IL-17 signaling and neuroimmunology: Psoriasis to Autism Spectrum Disorder

Asumi Kubo; Tetsuya Sasaki

doi:10.51094/jxiv.869

##article.authors##

Asumi Kubo Laboratory of Anatomy and Neuroscience, Faculty of Medicine, University of Tsukuba
Tetsuya Sasaki Laboratory of Anatomy and Neuroscience, Division of Life and Medical Sciences, Faculty of Medicine, University of Tsukuba https://orcid.org/0000-0002-7723-4417 https://researchmap.jp/tsasak

DOI:

https://doi.org/10.51094/jxiv.869

Keywords:

autism spectrum disorder, drug repositioning, IL-17/IL-17R inhibitors, neuroimmunology

Abstract

The IL-17 pathway is involved in diverse diseases, including psoriasis and autism spectrum disorder (ASD). IL-17 inhibitors have shown high efficacy in the treatment of psoriasis, and their indications are expanding to other autoimmune diseases; in ASD, it has been suggested that maternal IL-17 may affect fetal brain development, and existing psoriasis drugs may be applied to ASD interventions. In this paper, we discuss whether IL-17 inhibitors used for psoriasis treatment can be indicated for the prevention and treatment of autism. Further elucidation of the interaction between the immune system and the nervous system is expected to lead to the development of new therapeutic strategies.

Conflicts of Interest Disclosure

The authors declare that they have no competing interests.

Downloads *Displays the aggregated results up to the previous day.

Download data is not yet available.

Author Biographies

Asumi Kubo, Laboratory of Anatomy and Neuroscience, Faculty of Medicine, University of Tsukuba

Laboratory of Anatomy and Neuroscience, Division of Life and Medical Sciences, Faculty of Medicine, University of Tsukuba

College of Biology, School of Life and Environmental Sciences, University of Tsukuba

Tetsuya Sasaki, Laboratory of Anatomy and Neuroscience, Division of Life and Medical Sciences, Faculty of Medicine, University of Tsukuba

Laboratory of Anatomy and Neuroscience, Division of Life and Medical Sciences, Faculty of Medicine, University of Tsukuba

References

Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. Science. 2016 Aug 19;353(6301):772–7.

Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009 Jul 3;9(8):556–67.

Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010 Jul;10(7):479–89.

Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the yin and the yang. Trends Immunol [Internet]. 2017; Available from: https://www.cell.com/trends/immunology/fulltext/S1471-4906(17)30020-0

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014 Jul;71(1):141–50.

Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018 Feb;27(2):115–23.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–38.

Kenneth B. Gordon, M.D., Andrew Blauvelt, M.D., Kim A. Papp, M.D., Ph.D., Richard G. Langley, M.D., Thomas Luger, M.D., Mamitaro Ohtsuki, M.D., Ph.D., Kristian Reich, M.D., David Amato, D.O., Susan G. Ball, Ph.D., Daniel K. Braun, M.D., Ph.D., Gregory S. Cameron, Ph.D., Janelle Erickson, Ph.D., Robert J. Konrad, M.D., Talia M. Muram, M.D., Brian J. Nickoloff, M.D., Ph.D., Olawale O. Osuntokun, M.D., Roberta J. Secrest, Ph.D., Fangyi Zhao, Ph.D., Lotus Mallbris, M.D., Ph.D., and Craig L. Leonardi. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med [Internet]. Available from: http://dx.doi.org/ 10.1056/NEJMoa1512711

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct;373(14):1318–28.

Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405–17.

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct;373(14):1329–39.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–48.

Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017 Jun;76(6):1070–7.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4;375(5):422–34.

Blanco FJ, Möricke R, Dokoupilova E, Codding C, Neal J, Andersson M, et al. Secukinumab in active rheumatoid arthritis: A phase III randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol. 2017 Jun;69(6):1144–53.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–700.

Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016 Jul;263(7):1287–95.

Tome S, Sasaki T, Takahashi S, Takei Y. Elevated maternal retinoic acid-related orphan receptor-γt enhances the effect of polyinosinic-polycytidylic acid in inducing fetal loss. Exp Anim. 2019 Nov 6;68(4):491–7.

Asumi Kubo A, Sara Kamiya, Tetsuya Sasaki. Effects of Maternal Immune Activation and IL-17A on Abortion. Bio Clinica. 2024 Aug 10;39(1):38–40.

Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011 Jul;17(7):389–94.

Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016 Feb 26;351(6276):933–9.

Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017 Sep 8;23(9):1018–27.

Sasaki T, Tome S, Takei Y. Intraventricular IL-17A administration activates microglia and alters their localization in the mouse embryo cerebral cortex. Mol Brain. 2020 Jun 16;13(1):93.

Shin Yim Y, Park A, Berrios J, Lafourcade M, Pascual LM, Soares N, et al. Reversing behavioural abnormalities in mice exposed to maternal inflammation. Nature. 2017 Sep 28;549(7673):482–7.

Sasaki T, Nagata R, Takahashi S, Takei Y. Effects of RORγt overexpression on the murine central nervous system. Neuropsychopharmacol Rep. 2021 Mar;41(1):102–10.

Braunschweig D, Krakowiak P, Duncanson P, Boyce R, Hansen RL, Ashwood P, et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry. 2013 Jul 9;3(7):e277.

Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature. 2008 Jun;453(7198):1051–7.

Vuong HE, Hsiao EY. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder. Biol Psychiatry. 2017 Mar 1;81(5):411–23.

Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity. 2015 Oct 20;43(4):727–38.

Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, et al. Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry. 2017 Feb;22(2):273–9.

Appel JM. Ethical and Legal Aspects in the Treatment of Autism Spectrum Disorder. Focus . 2024 Apr;22(2):184–8.

Feng X, Xie H-G, Malhotra A, Yang CF. Biologics and Biosimilars: Drug Discovery and Clinical Applications. CRC Press; 2022. 528 p.

Egeberg A, Ottosen MB, Gniadecki R, Broesby‐Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2018 Feb 1;178(2):509–19.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006 Sep 22;126(6):1121–33.